Header Logo

Connection

ARGUN AKCAKANAT to Drug Monitoring

Back to Details
This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Drug Monitoring.
ARGUN AKCAKANAT
Connection Strength
0.035
Drug Monitoring
  1. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.